A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs GSK 1362885 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Jun 2010 Results presented at the 92nd Annual Meeting of the Endocrine Society.
    • 11 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top